Literature DB >> 15620682

Proteasome inhibition and Tau proteolysis: an unexpected regulation.

P Delobel1, O Leroy, M Hamdane, A V Sambo, A Delacourte, L Buée.   

Abstract

Increasing evidence suggests that an inhibition of the proteasome, as demonstrated in Parkinson's disease, might be involved in Alzheimer's disease. In this disease and other Tauopathies, Tau proteins are hyperphosphorylated and aggregated within degenerating neurons. In this state, Tau is also ubiquitinated, suggesting that the proteasome might be involved in Tau proteolysis. Thus, to investigate if proteasome inhibition leads to accumulation, hyperphosphorylation and aggregation of Tau, we used neuroblastoma cells overexpressing Tau proteins. Surprisingly, we showed that the inhibition of the proteasome led to a bidirectional degradation of Tau. Following this result, the cellular mechanisms that may degrade Tau were investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15620682      PMCID: PMC7130380          DOI: 10.1016/j.febslet.2004.11.018

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

1.  Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions.

Authors:  Tilman Grune; Diana Botzen; Martina Engels; Peter Voss; Barbara Kaiser; Tobias Jung; Stefanie Grimm; Gennady Ermak; Kelvin J A Davies
Journal:  Arch Biochem Biophys       Date:  2010-05-15       Impact factor: 4.013

2.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

Review 3.  The fine-tuning of proteolytic pathways in Alzheimer's disease.

Authors:  Valentina Cecarini; Laura Bonfili; Massimiliano Cuccioloni; Matteo Mozzicafreddo; Mauro Angeletti; Jeffrey N Keller; Anna Maria Eleuteri
Journal:  Cell Mol Life Sci       Date:  2016-04-27       Impact factor: 9.261

4.  Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.

Authors:  Chunyang Li; Shuzhen Chen; Ping Yue; Xingming Deng; Sagar Lonial; Fadlo R Khuri; Shi-Yong Sun
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

Review 5.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

6.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors:  Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

7.  Small-molecule mediated neuroprotection in an in situ model of tauopathy.

Authors:  Nicolette S Honson; Jordan R Jensen; Aida Abraha; Garth F Hall; Jeff Kuret
Journal:  Neurotox Res       Date:  2009-02-26       Impact factor: 3.911

8.  Concentration-dependent effects of proteasomal inhibition on tau processing in a cellular model of tauopathy.

Authors:  Tadanori Hamano; Tania F Gendron; Li-Wen Ko; Shu-Hui Yen
Journal:  Int J Clin Exp Pathol       Date:  2009-06-15

9.  Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing.

Authors:  Yipeng Wang; Marta Martinez-Vicente; Ulrike Krüger; Susmita Kaushik; Esther Wong; Eva-Maria Mandelkow; Ana Maria Cuervo; Eckhard Mandelkow
Journal:  Hum Mol Genet       Date:  2009-08-04       Impact factor: 6.150

10.  NPAS4 Facilitates the Autophagic Clearance of Endogenous Tau in Rat Cortical Neurons.

Authors:  Wenhui Fan; Yan Long; Yujie Lai; Xuefeng Wang; Guojun Chen; Binglin Zhu
Journal:  J Mol Neurosci       Date:  2015-12-03       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.